InMed Pharmaceuticals Inc (INM) Stock AnalysisINMInMed Pharmaceuticals Inc

InMed Pharmaceuticals Inc. is a pharmaceutical company. The Company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

InMed Pharmaceuticals is not a good buy right now due to its low RSI of 31.092, indicating oversold conditions, and a significant 1-year change of -36.11%. While the recent merger news may provide some potential upside, the current financial performance shows a troubling trend with a net income loss of -2,966,336 USD in Q3 2026 and a gross margin drop to 15.97% in Q2 2026, which raises concerns about its profitability and sustainability.